Business Wire

THALES

10.9.2019 09:32:03 CEST | Business Wire | Press release

Share
Fintech innovator Treezor chooses Thales Cloud HSM to Uphelp secure Banking-as-a-Service

Thales today announced that Treezor, the leading banking-as-a-service platform in France, has deployed its SafeNet Data Protection On Demand solution to provide security across its entire payment chain, from tier one banks and neo-banks to crowdfunding organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005069/en/

As an electronic money issuer, Treezor is bound by a variety of data privacy regulations and requirements, including requirements from the French Regulator (ACPR), the Mastercard network and the European Union’s General Data Protection Regulation (GDPR). Treezor is required to implement strong data security controls to protect personal financial information and other sensitive data. After evaluating several providers, Treezor selected SafeNet Data Protection On Demand (DPoD) due to its ability to provide a cost-effective and easy-to-use cloud HSM service as a highly secure root of trust for cryptographic operations.

“Innovation is the lifeblood of how we operate, but it should never come at the expense of security or vice versa,” said Eric Lassus, CEO of Treezor . “Part of our ethos is to work extremely closely with our clients to understand their needs, which led to the creation of our payment platform using standard APIs. As a result, we need a solution that meets our security, management and commercial needs.”

Treezor, recently acquired by Societe Generale, was familiar with the security advantages of HSMs, but wanted to minimize investments and on-going overheads, so it began investigating cloud-based offerings. Taking advantage of the 30-day free evaluation offered by Thales for its cloud-based HSM solution, Treezor was impressed by the ease of use and the speed it was able to deploy its test environment. During the evaluation phase of SafeNet Data Protection On Demand, the ‘point-and-click’ ease of use convinced Treezor that SafeNet Cloud HSM On Demand service provided the best solution in terms of cost, security and ease of implementation.

With SafeNet Data Protection On Demand, Treezor benefits from:

  • Rapid deployment and easy integration – Cloud HSM services were up and running and integrated into their systems in minutes
  • Service Level Availability – Unlike other Cloud HSM services on the market, SafeNet Data Protection On Demand comes with a 99.95% SLA
  • Predictable costs – Pricing is provided in a predictable way with all costs like redundancy and back-up services inclusive, meaning no hidden charges for high availability

Treezor’s strategy has led to a dramatic growth in two years, from issuing 100,000 cards and €400,000 of transactions in 2017 to over 500,000 cards and €5 billion in 2018.

With the scalability of SafeNet Cloud HSM On Demand, alongside its separation of duties, Treezor can offer each customer their own dedicated HSM service, bringing them safety in the knowledge that their financial and other sensitive data is segregated and protected.

“Working in the financial sector, trust is an extremely high parameter with which companies are judged by customers,” Lassus continued. “We chose Thales because of its stellar reputation in security, the ease-of-use of the whole solution and the high SLAs it guarantees. It’s vital too that we’re able to give our customers a clear insight into costs and availability of our services. The transparency and reliability we’ve received with SafeNet Data Protection On Demand is ideal for our needs of offering services simply, secure and costs effectively across our entire payment chain, from traditional banks to the most innovative fintech companies.”

Todd Moore, vice president of encryption products for cloud protection and licensing activity at Thales said: “The financial industry is one of the most regulated in the world, so it can sometimes be tricky for some to find that balance between innovation and compliance. With SafeNet Data Protection on Demand, Treezor can offer innovative solutions across its payment platform, while ensuring a transparent and secure approach that satisfies both regulators and customers.”

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.

 

About Treezor

Founded in 2016 by Éric Lassus and Xavier Labouret, Treezor is a French Bank-as-a-Service platform covering the entire payment chain through API based solutions. The fintech is an approved electronic money issuer and a Mastercard principal member. As a young and innovative company, Treezor devotes a significant part of its resources to develop new technologies in the field of open banking to support the strategy and service deployment of its customers.

PLEASE VISIT
Thales Group
Digital Security
Download HD photos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye